MIRM
Mirum reports Q3 sales of $185.7M, ups guidance
Mirum released Q3 2026 financial results and increased net product sales guidance to $715M-$720M. Additionally, the company received FDA approval for ATEBRIOZ and announced positive trial data for its late-stage pipeline.
Earnings|Guidance|Regulatory
Nov 3, 2026
sentiment +0.70
SEC filing ↗
BriefTape provides AI-summarized public SEC filings for informational purposes only. Content does not constitute investment advice. Always verify against source filings at sec.gov. BriefTape is not a registered investment adviser, broker-dealer, or financial advisor.